STOCK TITAN
  1. Home
  2. News
  3. BCTX

Briacell Therapeutics Corp. Common Shares - BCTX STOCK NEWS

Welcome to our dedicated page for Briacell Therapeutics Common Shares news (Ticker: BCTX), a resource for investors and traders seeking the latest updates and insights on Briacell Therapeutics Common Shares stock.

BriaCell Therapeutics Corp (NASDAQ: BCTX) is a pioneering biotechnology company headquartered in Los Angeles, specializing in the development of immunotherapy treatments for cancer management. The company’s innovative approach focuses on harnessing the body's immune system to target and eliminate cancer cells, providing new hope for patients battling this devastating disease.

Central to BriaCell's portfolio is the BriaVax vaccine, which has shown promising results in early-phase clinical trials. In two compelling FDA Phase I studies involving late-stage breast cancer patients, BriaVax demonstrated unique and unprecedented outcomes, showcasing its potential as a groundbreaking treatment. Building on these successes, BriaCell is aggressively advancing towards a Phase I/II clinical trial, aiming to expand its vaccine's application to a larger cohort of breast cancer patients.

In addition to BriaVax, the company is also developing Bria-IMT, currently in a Phase I/IIa clinical trial targeting metastatic breast cancer. Bria-IMT represents a targeted and safe approach to treating advanced-stage breast cancer, reinforcing BriaCell's commitment to innovative cancer therapies. Another significant development in their pipeline is the Bria-OTS ('off-the-shelf') personalized immunotherapy, designed to match the patient's HLA type, further customizing and enhancing the treatment's effectiveness.

While BriaCell's current focus remains on breast cancer, the company is exploring the potential of applying its vaccine technology to other cancer types, broadening its impact in the oncology field. With a strategic vision and robust pipeline, BriaCell is poised to make significant contributions to cancer treatment and patient care.

For more detailed updates and the latest news about BriaCell Therapeutics Corp, visit their website or contact them directly. The company remains committed to transparency and regularly shares progress on their groundbreaking research and clinical trials.

News

BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies

Rhea-AI Summary
BriaCell Therapeutics Corp. signs an agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ and Bria-PROS+, its novel personalized cancer vaccines. The collaboration with Dr. Paula Pohlmann from MD Anderson Cancer Center marks a significant milestone in BriaCell's mission to revolutionize cancer care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.05%
Tags
clinical trial
-
News

BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference

Rhea-AI Summary
BriaCell Therapeutics Corp. announces the presentation of three posters at the 2024 AACR Annual Meeting, showcasing the efficacy and safety of their immunotherapies in cancer care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.24%
Tags
conferences clinical trial
-
News

BriaCell Provides Update on Alleged Illegal Trading of Public Securities

Rhea-AI Summary
BriaCell Therapeutics Corp. updates on the investigation of alleged illegal trading activity of its securities by filing complaints with FINRA and CIRO after identifying significant settlement share imbalances.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.57%
Tags
none
News

BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case

Rhea-AI Summary
BriaCell Therapeutics Corp. reports a preliminary disease control rate of 61% in evaluable Phase 2 advanced breast cancer patients treated with BriaCell’s Bria-IMT™ regimen in their open pivotal Phase 3 study. Additionally, a disease control rate of 50% was observed in patients who had failed prior antibody-drug conjugate (ADC) therapy. A notable responder who had failed 4 prior therapies, including ADC therapy with a metastatic liver tumor, saw significant improvement following BriaCell treatment. The company is encouraged by the clinical benefits observed and looks forward to sharing additional clinical data in the coming months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
clinical trial
-
News

Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing

Rhea-AI Summary
BriaCell Therapeutics Corp. announces the initiation of Good Manufacturing Practice (GMP) manufacturing of its lead candidate for treating prostate cancer, Bria-Pros+. The company's next generation personalized immunotherapy platform, Bria-Pros+, is capable of activating multiple types of immune cells, including helper T cells, cytotoxic (killer) T cells, and natural killer cells. This represents a major milestone for BriaCell, as GMP manufacturing will provide clinical supplies for planned clinical trial use.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.34%
Tags
none
-
News

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

Rhea-AI Summary
BriaCell Therapeutics Corp. announces the results of its annual general meeting of shareholders, with an overwhelming vote in favor of all proposed resolutions. The meeting saw a total of 5,375,071 common shares voted, representing 33.63% of the Company's issued and outstanding Common Shares. Shareholders voted in favor of re-appointing MNP LLP as auditors and authorizing the directors' remuneration, as well as the election of seven directors. The formal report on voting results will be filed on the Company's SEDAR+ profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
none
News

BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer

Rhea-AI Summary
BriaCell Therapeutics Corp. (BCTX) reports significant reduction in metastatic breast cancer tumor behind the eye after 3 cycles of Bria-IMT™ combination regimen. The patient had failed 7 prior regimens, including antibody-drug conjugate therapy, and experienced reduced proptosis and ocular pain. Bria-IMT™ showed robust anti-tumor activity in difficult-to-reach tumors, with a 71% intracranial objective response rate in breast cancer patients with CNS metastases. The pivotal Phase 3 study in advanced breast cancer is ongoing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.6%
Tags
none
-
News

BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients

Rhea-AI Summary
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) reports 71% intracranial objective response rate (iORR) in advanced breast cancer patients with CNS metastases treated with Bria-IMT™ regimen, demonstrating clinical efficacy and potential market approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.19%
Tags
none
-
News

BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset

Rhea-AI Summary
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) reported unprecedented preliminary survival and clinical benefit data in a new subset of advanced breast cancer patients treated with BriaCell’s Bria-IMT™ regimen. Overall Survival (OS) data exceeded similar studies, with a median OS up to twice that reported in the literature. Progression Free Survival (PFS) was similar or better than the last regimen in 40% of the patients, and a disease control rate of 40% was observed in evaluable patients, further indicating clinical benefit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.55%
Tags
none
News

BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS

Rhea-AI Summary
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) announced outstanding topline survival and clinical benefit data in advanced metastatic breast cancer patients treated with Bria-IMT™ in combination with an immune check point inhibitor. The median overall survival was 13.4 months, a marked improvement over the benchmark of 6.7-9.8 months for similar patients. 32 out of 42 patients treated since 2022 remain alive, indicating consistently strong survival benefit. All patients were able to receive therapy with no toxicity-related discontinuations. The Phase 2 study is fully enrolled with 54 advanced metastatic breast cancer patients, showing excellent overall survival and tolerability, as well as a positive immune response.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.8%
Tags
none

FAQ

What is the current stock price of Briacell Therapeutics Common Shares (BCTX)?

The current stock price of Briacell Therapeutics Common Shares (BCTX) is $0.729 as of September 6, 2024.

What is the market cap of Briacell Therapeutics Common Shares (BCTX)?

The market cap of Briacell Therapeutics Common Shares (BCTX) is approximately 12.7M.

What does BriaCell Therapeutics Corp do?

BriaCell Therapeutics Corp specializes in developing immunotherapy treatments for cancer, focusing primarily on breast cancer.

What are the main products of BriaCell Therapeutics Corp?

BriaCell's main products include the BriaVax vaccine, Bria-IMT, and Bria-OTS, which are all designed to treat advanced-stage breast cancer.

What is BriaVax?

BriaVax is a patented vaccine developed by BriaCell for treating late-stage breast cancer, showing promising results in early clinical trials.

What clinical trials is BriaCell currently conducting?

BriaCell is conducting a Phase I/IIa clinical trial for Bria-IMT in metastatic breast cancer and is planning to launch a Phase I/II trial for BriaVax.

Where is BriaCell Therapeutics Corp headquartered?

BriaCell Therapeutics Corp is headquartered in Los Angeles, California.

Is BriaCell focusing only on breast cancer?

Currently, BriaCell's primary focus is on breast cancer, but the company is exploring the potential to apply its vaccine technology to other cancer types.

How can I contact BriaCell Therapeutics Corp?

You can contact BriaCell through their website or by reaching out to their President & CEO, Dr. William V. Williams, at 1-888-485-6340 or info@briacell.com.

What makes BriaCell's immunotherapy approach unique?

BriaCell's approach leverages the body's immune system to target cancer cells, with products like Bria-OTS offering personalized treatment by matching the patient's HLA type.

Who are the primary contacts for media and investor relations at BriaCell?

For media relations, contact Jules Abraham at CORE IR; for investor relations, contact CORE IR at investors@briacell.com.

Where can I find the latest news about BriaCell Therapeutics Corp?

The latest news about BriaCell can be found on their website and through regular updates provided via their press releases and news announcements.

Stock BCTX logo
Briacell Therapeutics Corp. Common Shares

Nasdaq:BCTX

BCTX Rankings

#5378 Ranked by Market Cap
N/A Ranked by Dividends

BCTX Stock Data

12.70M
18.29M
15.56%
10.97%
2.54%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WEST VANCOUVER